Odyssey Thera will analyze drug candidates from a number of preclinical programs for Mitsubishi Tanabe Pharma. Odyssey Thera will apply its patented protein-fragment complementation assay, high-context screening infrastructure, institutional knowledge, and data analysis strategies in the collaboration to yield insights related to drug selectivity, safety, and mechanisms of action.


Odyssey also reports the issuance of a Japanese patent entitled, “Protein fragment complementation assays for the detection of biological or drug interactions.”

Previous articleCARBON DIOXIDE TRANSPORT PROTEIN IN MICROALGAE IDENTIFIED
Next articlePfizer to Extend Use of Patient Selection Technology from Monogram